Proteins involved in regulation of adipocytes and uses related thereto
OwnerMatthias Mann, Alexandre V. Podtelejnikov +3inventors
InventorsMatthias Mann, Alexandre V. Podtelejnikov, Blagoy Andonov Blagoev, Irina Hristova Kratchmarova, Akhilesh Pandey
Life of this patent
Estimating the term…
Abstract
The invention relates to the identification and quantification of proteins differentially expressed during adipogenesis. More specifically, the invention relates to methods for identifying and/or quantitating proteins differentially expressed in one or more specific stage(s) of adipocyte differentiation, using mass spectrometry. The invention also provides those differentially expressed genes as marker genes of adipogenesis. The invention further provides treatment methods for patients suffering from conditions associated with hyper- or hypo-adipogenesis.
Claims36
A method for identifying a protein differentially expressed between a first and a second populations of cells of adipose lineage, comprising:
- (i) obtaining a first protein sample from said first populations of cells, and a second protein sample from said second populations of cells;
- (ii) separating proteins in said first and second protein samples;
- (iii) identifying and isolating one or more proteins, if any, differentially expressed in said first and said second populations of cells;
- and
- (iv) determining, by mass spectrometry, the identity/sequence of said differentially expressed proteins isolated in (iii).
A method of modulating adipogenesis in a cell, comprising contacting the cell with an effective amount of an agent selected from:
- pigment epithelium derived factor (PEDF), haptoglobin, neutrophil gelatinase associated lipocalin, hippocampal cholinergic neurostimulating peptide, stromal cell derived factor-1/pre-B cell growth stimulating factor, calumenin, calvasculin, colligen-1, gelsolin, osteoblast specific factor 2, follistatin-like protein or calgizzarin.
A method of determinig the differentiation stage of adipogenesis in a cell, comprising identifying one or more agents whose expression level is substantially changed during adipogenesis, and determining the expression level of said one or more agents during adipogenesis of said cell, thereby determining the differentiation stage of adipogenesis in said cell.
A method for quantitating a protein differentially expressed between a first and a second populations of cells of adipose lineage, comprising:
- (i) obtaining a first protein sample from said first populations of cells, and a second protein sample from said second populations of cells;
- (ii) separating proteins in said first and second protein samples;
- (iii) identifying and isolating one or more proteins, if any, differentially expressed in said first and said second populations of cells;
- and
- (iv) determining, by mass spectrometry, the identity and relative quantity of said differentially expressed proteins isolated in (iii).
A method of conducting a drug discovery business comprising:
- (i) identifying, using the method of claim x, one or more agents capable of modulating adipogenesis;
- (ii) conducting therapeutic profiling of agents identified in step (i), or further analogs thereof, for efficacy and toxicity in animals;
- and
- (iii) formulating a pharmaceutical preparation including one or more agents identified in step (ii) as having an acceptable therapeutic profile.
A method of conducting a target discovery business comprising:
- (i) identifying, using the method of claim x, one or more agents capable of modulating adipogenesis;
- (ii) (optionally) conducting therapeutic profiling of agents identified in step (i) for efficacy and toxicity in animals;
- and
- (iii) licensing, to a third party, the rights for further drug development and/or sales for gents identified in step (i), or analogs thereof.
Dependencies are inferred from the claim text.